|Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.||
Drug Twilight Zone
The Journal believes that the Tysabri withdrawal has little to do with science and a lot to do with politics—Biogen and Elan didn’t want “to have their names dragged before Capitol Hill cameras by Ted Kennedy or Chuck Grassley.” So as two companies minimize their risk profile for a few months, MS patients have to go back to their old, less effective treatments. Perhaps Kennedy and Grassley should hold a hearing on that problem.
|home spotlight commentary research events news about contact links archives|